By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced today that it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for two new drugs: HRS8179 for injection and HRS-1893 tablets.
HRS8179: Targeting Severe Cerebral Edema
HRS8179 is designed to address severe cerebral edema following large hemispheric infarction, a leading cause of death in stroke patients. The drug works by reducing sodium ion influx, which helps mitigate brain edema formation post-stroke and alleviates cerebral infarction.
HRS-1893: Heart Failure with Preserved Ejection Fraction
HRS-1893 tablets are a highly selective small-molecule inhibitor of cardiac myosin. By inhibiting cardiac myosin ATPase activity, the drug aims to normalize myocardial contractility, reduce left ventricular hypertrophy, and improve diastolic compliance. It is intended for the treatment of heart failure with preserved ejection fraction.-Fineline Info & Tech